Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$43.83
+20.6%
$32.08
$19.80
$44.41
$2.49B0.77815,084 shs2.03 million shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$28.98
+3.5%
$27.86
$14.02
$44.32
$5.42B1.081.71 million shs1.57 million shs
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$17.73
-4.3%
$18.49
$10.68
$21.92
$3.23B0.75114,717 shs157,744 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$7.72
+4.0%
$6.52
$5.12
$19.54
$564.88M0.771.06 million shs1.49 million shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
+20.61%+39.14%+26.90%+39.72%+68.25%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+3.46%+3.72%+4.13%-2.09%+103.23%
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
-4.32%-5.34%-7.42%+28.20%+41.84%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
+4.04%+25.32%+23.32%-3.98%-59.48%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
1.8797 of 5 stars
1.33.00.04.72.40.80.0
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
4.6566 of 5 stars
4.52.00.03.93.13.30.6
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
1.3907 of 5 stars
3.43.00.00.02.00.00.6
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
1.0119 of 5 stars
3.30.00.00.02.90.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
2.50
Moderate Buy$35.00-20.15% Downside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.92
Moderate Buy$47.6264.30% Upside
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
2.75
Moderate Buy$29.7067.51% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.62
Moderate Buy$15.58101.86% Upside

Current Analyst Ratings

Latest TVTX, AGIO, BBIO, and HCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/30/2024
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$43.00 ➝ $43.00
5/28/2024
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$70.00 ➝ $70.00
5/28/2024
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$51.00 ➝ $47.00
5/20/2024
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$47.00 ➝ $43.00
5/14/2024
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$50.00
5/13/2024
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/7/2024
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00
5/7/2024
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $18.00
5/3/2024
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$29.00 ➝ $33.00
4/24/2024
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $19.00
4/17/2024
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$13.00
(Data available from 6/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$26.82M92.78N/AN/A$14.51 per share3.02
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$218.60M24.81N/AN/A($7.72) per share-3.75
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$838M3.69$0.60 per share29.63$4.27 per share4.15
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$145.24M4.05N/AN/A$2.67 per share2.89

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$352.09M-$6.32N/AN/AN/A-1,199.26%-41.41%-36.36%8/1/2024 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$643.20M-$3.22N/AN/AN/A-246.24%N/A-80.12%8/1/2024 (Estimated)
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$100.78MN/A0.0036.94N/AN/AN/AN/A6/5/2024 (Estimated)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$111.40M-$2.10N/AN/AN/A-87.94%-238.06%-52.87%8/1/2024 (Estimated)

Latest TVTX, AGIO, BBIO, and HCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024Q1 2024
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.98-$1.76-$0.78-$1.76$43.46 million$41.40 million      
5/2/2024Q1 2024
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.65-$1.45+$0.20-$1.45$8.37 million$8.19 million      
5/2/2024Q1 2024
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.40-$0.05+$0.35$0.10$140.06 million$211.12 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
12.84
12.39
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
5.54
5.54
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
0.06
2.72
2.60
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
5.10
2.78
2.75

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
8.82%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
4.93%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
24.66%
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
3.60%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
38356.77 million53.97 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
550187.13 million140.98 millionOptionable
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
1,988174.25 million167.98 millionNot Optionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
38076.13 million73.04 millionOptionable

TVTX, AGIO, BBIO, and HCM Headlines

Recent News About These Companies

Gossamer Bio: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Agios Pharmaceuticals logo

Agios Pharmaceuticals

NASDAQ:AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
BridgeBio Pharma logo

BridgeBio Pharma

NASDAQ:BBIO
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
HUTCHMED logo

HUTCHMED

NASDAQ:HCM
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Travere Therapeutics logo

Travere Therapeutics

NASDAQ:TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.